Illuminating HDL--is it still a viable therapeutic target?

N Engl J Med. 2007 Nov 22;357(21):2180-3. doi: 10.1056/NEJMe0707210. Epub 2007 Nov 5.
No abstract available

Publication types

  • Comment
  • Editorial

MeSH terms

  • Anticholesteremic Agents / adverse effects*
  • Anticholesteremic Agents / therapeutic use
  • Apolipoprotein A-I / metabolism
  • Cardiovascular Diseases / chemically induced
  • Cardiovascular Diseases / drug therapy
  • Cardiovascular Diseases / mortality*
  • Cholesterol Ester Transfer Proteins / antagonists & inhibitors*
  • Cholesterol, HDL / blood*
  • Humans
  • Quinolines / adverse effects*
  • Up-Regulation

Substances

  • Anticholesteremic Agents
  • Apolipoprotein A-I
  • Cholesterol Ester Transfer Proteins
  • Cholesterol, HDL
  • Quinolines
  • torcetrapib